Clinical trial NCT00486018: A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)
Official title: A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Macular Edema
Retinal Vein Occlusion
Keywords: Lucentis
RVO
BRVO
Edema
Lead sponsor: Genentech, Inc.
Sponsor class: INDUSTRY
First posted: 2007-06-13
Enrollment: 397
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to branch retinal vein occlusion (BRVO); 397 patients with BRVO were enrolled at 93 investigational sites in the United States. The study included a treatment period (6 months) and an observation period (6 months).


Eligibility criteria: Inclusion Criteria:

* Willingness to provide signed Informed Consent Form
* Age ≥ 18 years
* For sexually active women of childbearing potential, use of an appropriate form of contraception (or abstinence) for the duration of the study
* Ability and willingness to return for all scheduled visits and assessments

Ocular Inclusion Criterion (Study Eye):

* Foveal center-involved macular edema secondary to BRVO
* BCVA using ETDRS charts of 20/40 to 20/400 (Snellen equivalent)
* Mean central subfield thickness ≥ 250 μm on two optical coherence tomography (OCT) measurements (at screening \[confirmed by the central reading center\] and Day 0 \[confirmed by the evaluating physician\])
* Media clarity, pupillary dilation, and participant cooperation sufficient to obtain adequate fundus photographs

Exclusion Criteria:

* History of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0
* History of any anti-vascular endothelial growth factor (VEGF) treatment in fellow eye within 3 months prior to Day 0
* History of any systemic anti-VEGF or pro-VEGF treatment within 6 months prior to Day 0
* History of allergy to fluorescein
* History of allergy to ranibizumab injection or related molecule
* Relevant systemic disease that may be associated with increased systemic VEGF levels (namely, all active malignancies); history of successfully treated malignancies is not an exclusion criterion
* Uncontrolled blood pressure
* Pregnancy or lactation
* Any condition that, in the opinion of the investigator, would preclude participation in the study (e.g., chronic alcoholism or drug abuse, personality disorder or use of major tranquilizers, indicated difficulty in long-term follow-up, and likelihood of survival of less than 1 year)
* Participation in an investigational trial within 30 days prior to Day 0 that involved treatment with any drug (excluding vitamins and minerals) or device that has not received regulatory approval at time of study entry

Ocular Exclusion Criteria (Study Eye):

* Prior episode of retinal vein occlusion (RVO)
* Brisk afferent pupillary defect
* History of radial optic neurotomy or sheathotomy
* History or presence of age-related macular degeneration (AMD; dry or wet form)
* History of any anti-VEGF treatment in the study eye within 3 months prior to Day 0
* History of laser photocoagulation for macular edema within 4 months prior to Day 0
* History of panretinal scatter photocoagulation or sector laser photocoagulation within 3 months prior to randomization or anticipated within the next 4 months following randomization
* History of intraocular corticosteroid use within 3 months prior to Day 0
* History of pars plana vitrectomy
* History of intraocular surgery (including cataract extraction, scleral buckle, etc.) within 2 months prior to Day 0 or anticipated within the next 7 months following Day 0
* History of yttrium-aluminum-garnet capsulotomy performed within 2 months prior to Day 0
* Previous filtration surgery in the study eye
* History of herpetic ocular infection
* History of ocular toxoplasmosis
* History of rhegmatogenous retinal detachment
* History of idiopathic central serous chorioretinopathy
* Evidence upon examination of vitreoretinal interface disease (e.g., vitreomacular traction, epiretinal membrane), either on clinical examination or OCT, thought to be contributing to macular edema
* An eye that, in the investigator's opinion, would not benefit from resolution of macular edema, such as eyes with foveal atrophy, dense pigmentary changes, or dense subfoveal hard exudates
* Presence of an ocular condition that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the study (e.g., uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass syndrome, or prior macula-off rhegmatogenous retinal detachment)
* Visually significant hemorrhage obscuring the fovea and felt to be a major contributor to reduced visual acuity
* Presence of a substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more (i.e., a 20/40 cataract)
* Aphakia
* Relevant ocular disease that may be associated with increased intraocular VEGF levels (namely, uveitis, neovascular glaucoma, neovascular AMD, diabetic retinopathy, diabetic maculopathy, or ocular ischemic syndrome)
* Improvement of \> 10 letters on best corrected visual acuity (BCVA) between screening and Day 0

Primary outcomes:
measure: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months
timeFrame: Baseline and 6 months
Secondary outcomes:
measure: Percentage of Participants Who Gained ≥ 15 Letters in BCVA Score at Month 6 Compared With Baseline
timeFrame: Baseline and 6 months
measure: Percentage of Participants Who Lost < 15 Letters in BCVA Score at Month 6 Compared With Baseline
timeFrame: Baseline and 6 months
measure: Percentage of Participants With a Central Foveal Thickness of ≤ 250 μm at Month 6
timeFrame: 6 months
measure: Mean Absolute Change From Baseline in Central Foveal Thickness at Month 6
timeFrame: Baseline and 6 months
measure: Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Near Activities Subscale Score at Month 6
timeFrame: Baseline and 6 months
measure: Mean Change From Baseline in the NEI VFQ-25 Distance Activities Subscale Score at Month 6
timeFrame: Baseline and 6 months
Other outcomes:
Locations:
Study officials:
affiliation: Genentech, Inc.
name: Roman Rubio, M.D.
role: STUDY_DIRECTOR
References:
citation: Suner IJ, Bressler NM, Varma R, Lee P, Dolan CM, Ward J, Colman S, Rubio RG. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmol. 2013 Jul;131(7):851-6. doi: 10.1001/jamaophthalmol.2013.114.
citation: Bhisitkul RB, Campochiaro PA, Shapiro H, Rubio RG. Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology. 2013 May;120(5):1057-63. doi: 10.1016/j.ophtha.2012.11.011. Epub 2013 Feb 14.